As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy.
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.